Prognostic relevance of (18)F-FDG PET/CT in carcinoma of unknown primary

Clin Nucl Med. 2014 Feb;39(2):131-5. doi: 10.1097/RLU.0000000000000304.

Abstract

Objectives: The aim of this study was to assess whether F-FDG PET combined with x-ray CT (F-FDG PET/CT) findings have a prognostic impact in patients with carcinoma of unknown primary (CUP).

Patients and methods: Seventy patients with CUP who were referred for F-FDG PET/CT were included. F-FDG PET/CT results were checked against available histologic diagnosis and follow-up data. For each patient, the SUVmax of the lesion with maximum uptake was measured.

Results: In 26% of the patients, a primary tumor was identified. The follow-up period after F-FDG PET/CT scan ranged between 3 and 45 months. Kaplan-Meier analysis revealed 1-year survival rates of 92% in the group without evidence of malignancy on F-FDG PET/CT, 78% in the group with locoregional disease, and 34% in the group with extensive disease on F-FDG PET/CT. Three-year survival rates in these groups were 73%, 71%, and 23%, respectively (P = 0.001). There was no significant survival difference between patients with regionally confined disease without identification of the primary tumor and those in whom the primary tumor was identified on F-FDG PET/CT (P = 0.25). This was also the case for patients with extensive disease (P = 0.26). The SUVmax of the lesion with maximum uptake was not significantly related to survival (P = 0.56).

Conclusions: F-FDG PET/CT is a helpful tool for the identification of the primary tumor in patients with CUP; it is also able to provide an accurate assessment of prognosis based on the extent of the disease without the need for identification of the primary tumor.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biological Transport
  • Female
  • Fluorodeoxyglucose F18* / metabolism
  • Humans
  • Male
  • Middle Aged
  • Multimodal Imaging*
  • Neoplasms, Unknown Primary / diagnostic imaging*
  • Neoplasms, Unknown Primary / metabolism
  • Positron-Emission Tomography*
  • Prognosis
  • Retrospective Studies
  • Tomography, X-Ray Computed*

Substances

  • Fluorodeoxyglucose F18